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Abstract
Background: Physician participation in clinical research recruitment efforts is critical to many
studies' success, but it is often limited. Use of an Electronic Health Record (EHR)-based, point-of-
care Clinical Trial Alert (CTA) approach has led to significant increases in physician-generated
recruitment and holds promise for wider benefit. However, little is known about physicians'
decision-making regarding recruitment in EHR-equipped settings or the use of such EHR-based
approaches. We sought to assess physicians' perceptions about recruitment in general and using
the CTA approach in particular.
Methods: We developed and delivered a Web-based survey consisting of 15 multiple-choice and
free-text questions. Participants included the 114 physician subjects (10 endocrinologists and 104
general internists) who were exposed to CTAs during our preceding 4-month intervention study.
Response data were descriptively analyzed, and key findings were compared between groups using
appropriate statistical tests.
Results: Sixty-nine physicians (61%) responded during the 10-week survey period. Respondents
and non-respondents did not differ significantly. Twenty-seven percent of respondents felt very
comfortable recruiting patients to trials in general, and 77% appreciated being reminded about a
trial via a CTA. Only 11% percent felt the CTA was difficult to use, and 27% felt it was more than
somewhat intrusive. Among those who ignored all CTAs, 37% cited a lack of time, 28% knowledge
of the patient's ineligibility, and 13% limited knowledge about the trial as their most common
reason. Thirty-eight percent wanted more information about the trial presented in the CTA, and
73% were interested in seeing CTAs for future trials. Comments and suggestions were submitted
by 33% of respondents and included suggestions for improvement of the CTA approach.
Conclusion: Most physicians were comfortable recruiting patients for clinical trials at the point-
of-care, found the EHR-based CTA approach useful and would like to see it used in the future.
These findings provide insight into the perceived utility of this EHR-based approach to subject
recruitment, suggest ways it might be improved, and add to the limited body of knowledge
regarding physicians' attitudes toward clinical trial recruitment in EHR-equipped settings.
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Background
Physician participation is critical to the successes of most
clinical trial recruitment efforts. Not only do clinicians
play a vital role by identifying potentially eligible subjects,
but patients are much more likely to participate in a study
if their physician has suggested it to them [1]. Unfortu-
nately, the identification and recruitment of eligible
patients during the course of busy clinical practice can be
difficult. In order to successfully recruit patients, physi-
cians engaging in traditional recruitment have to remem-
ber which local clinical trials are active, recall the trial's
details in order to determine patient eligibility, take time
to explain the trial's details to potentially eligible patients,
and often take more time to perform other recruitment
activities. Doing all of this while also attempting to pro-
vide the individual patient with good care during a short
clinic visit can be difficult, at best. Current privacy regula-
tions add further challenges to overcome in solving this
problem [2].
As a consequence, few clinicians, mostly those in univer-
sity settings, do most of the recruiting for clinical trials
[1,3,4]. Even in fields like oncology where clinical trial
participation is considered optimal for many patients,
only about 3% of eligible patients are enrolled into clini-
cal trials and enrollment is often not representative of the
general population [3,5,6]. In addition to frustrating
progress, these factors can introduce bias to the trial and
prevent some patients from receiving potentially benefi-
cial 'state-of-the-art' therapy.
Numerous technological approaches have been devel-
oped in attempts to enhance clinical trial recruitment [7-
14]. Some have shown promise by using computerized
clinical databases to automate the identification of poten-
tially eligible patients [15,16]. Electronic Health Record
(EHR)-based approaches have also been described,
though mostly in specialized settings and few have dem-
onstrated significant benefit in controlled studies [17-20].
Until recently, whether comprehensive EHRs could be lev-
eraged for the benefit of clinical trial recruitment at the
point-of-care as effectively as they have been for patient
safety and healthcare quality remained to be determined
[21].
The Clinical Trial Alert Approach
In 2004, we developed an EHR-based Clinical Trial Alert
(CTA) approach. The approach was designed to overcome
many of the known obstacles to trial recruitment by phy-
sicians while complying with current privacy regulations
[22]. We conducted a before-after intervention study of
the CTA approach applied to a large, multi-center, NIH-
sponsored type 2 diabetes mellitus clinical trial, the
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study for which the Cleveland Clinic was a
study site. During our 4- month CTA intervention phase,
the system alerted physicians to patients whose EHR data
met selected trial eligibility criteria [23]. Upon triggering,
the CTA served to remind the clinician about the trial and
to facilitate referral of interested patients to a clinical
trial's coordinator. Our subjects for this study were the
114 staff physicians (10 endocrinologists, 104 general
internists) practicing at one of our health system's Internal
Medicine and Endocrinology referral-center-based and
community-based clinics. When presented with the CTA,
physicians could choose to ignore the CTA or to use it.
In our intervention study, CTA use resulted in significant
increase in the number of physicians participating in
recruitment activities and in their rates of subject referrals
and enrollments to the trial compared to baseline rates
[23]. During the intervention study, all 114 physician sub-
jects received at least one CTA to which they could
respond. From among those, 48 (42%) participated by
attending to and processing at least one CTA order form
while the remainder ignored all CTAs presented to them.
Of those who participated by attending to at least one
alert during the intervention phase, 42 (88%) referred at
least one patient to the trial coordinator, and 11 (23%)
generated at least one enrollment. The number of physi-
cians referring patients after CTA activation increased
more than eight-fold, from 5 before to 42 after (P  <
0.001). In addition, physician-generated referral rates
increased more than ten-fold, from 5.7/month before
CTA activation to 59.5/month afterward (P < 0.001), and
enrolment rates more than doubled, from 2.9/month
before to 6.0/month after (P  = 0.007). While general
internists had not contributed to recruitment before, they
generated 170 (71%) of the referrals and 7 (29%) of the
enrollments after CTA activation. CTA use was also associ-
ated with a substantial referral rate increase of 47%
among endocrinologists. Despite these improvements in
overall physician recruitment to this trial after CTA activa-
tion, 52% of physicians did not use the CTA even once
and nearly 90% of all CTAs triggered were ignored by phy-
sicians.
Purpose for the Survey
While the preceding intervention study indicated that the
CTA approach had a significant impact on recruitment
and enrollment rates by physicians, it also revealed con-
siderable inefficiencies. Moreover, the intervention study
was not designed to answer certain important questions
about physicians' attitudes and reasons for using or dis-
missing the EHR-based recruitment alerts. Despite prior
research having been conducted in the areas of point-of-
care recruitment and computerized clinical decision sup-
port, little is known about how physicians feel about
point-of-care recruitment in EHR-equipped settings, and
we know of no reports concerning their perceptions onBMC Medical Informatics and Decision Making 2008, 8:13 http://www.biomedcentral.com/1472-6947/8/13
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using EHRs to facilitate point-of-care recruitment in the
manner allowed by the CTA approach.
Therefore, we undertook a survey of those physicians who
were exposed to CTAs during our recently completed
intervention study. Our objective was to assess their per-
ceptions of the CTA approach and of trial recruitment in
general in order to better understand the findings of our
intervention study and to inform further development,
application, and evaluation of the EHR-based approaches
to research subject recruitment.
Methods
To develop our 15-question survey (Table 1), we drew
upon factors identified in prior research studies to influ-
ence physician participation in trial recruitment and their
use of similar EHR-based technologies. Questions were
organized and delivered to participants using a commer-
cial, Web-based survey service (SurveyMonkey.com).
Participation in the IRB approved survey was solicited via
email from all physicians who were targeted for the CTA
intervention. These included the 10 endocrinologists and
104 general internists on staff at the main campus and
community based endocrinology and general internal
medicine clinics of the Cleveland Clinic who had been
exposed to the CTA at least once over the prior 4-month
intervention study. Among the endocrinologist subjects,
one was the site Principal Investigator for the clinical trial
to which the CTA intervention was applied.
Physician subjects could respond to the Web-based survey
or to an email version. Up to three reminders were sent to
those who had not responded over the 10-week survey
period. Responses were transferred onto a computerized
spreadsheet. Response frequencies were calculated and
the data were descriptively analyzed. Differences between
groups over relevant variables were tested using Fisher's
exact test. Narrative comments were coded and catego-
rized independently by two authors and agreement on
final categorizations was finally achieved via an iterative
discussion process.
Results
Sixty-nine physicians (61%) responded during the 10-
week survey period. All but seven responded via the Web-
based survey instrument, with the rest responding via
Email. A greater proportion of endocrinologists (90%)
than internists (58%) responded, P = 0.09. Respondents
were not significantly more likely to be CTA users (58%)
than non-users (42%), P = 0.13. Even among respondents
who opted to review CTAs when presented rather than
simply dismiss them (i.e. CTA users), many did not
encounter a patient suitable for referral. Indeed, nearly
half (48%) of all survey respondents did not use the CTA
to refer any patients during our study.
General Recruitment Issues
Most respondents (83%) felt at least somewhat comfortable
discussing participation in any clinical trial with 27% feel-
ing  very comfortable. Endocrinologists and general
internists varied in their levels of comfort (Figure 1).
Respondents were slightly more comfortable discussing
participation in the associated type 2 diabetes mellitus
clinical trial that was the focus of our CTA intervention.
Overall, 31% felt very comfortable recruiting for this partic-
ular trial, 100% of endocrinologists and 20% of internists.
Thirty-two percent of respondents reported not knowing
about the diabetes trial prior to CTA activation despite
being exposed to traditional efforts to inform them of the
trial and encourage them to participate (e.g. emails, dis-
cussion at meetings, posted information about the trial in
the clinic setting).
Use and perceptions of the CTA approach
Most respondents (77%) appreciated being reminded
about the trial via CTA during the patient encounter.
Though high even among subgroups, level of appreciation
varied somewhat by degree of specialization as well as
between CTA-users and CTA non-users (Figure 2). Despite
these levels of appreciation, 79% stated that they dis-
missed CTAs sometimes (54%) or every time (25%), with
only 9% indicating they used the CTA to consider patients
for referral every time it appeared. These reported rates
were consistent with those observed by direct query of the
system during the preceding intervention study. When
asked to rank their reasons for dismissing a CTA, 37%
cited a lack of time, 28% cited knowledge that the patient
would not qualify, 13% cited limited knowledge about
the trial, and only 4% cited concern about adversely
impacting the doctor-patient relationship as their most
common reason. Overall, 38% wanted the CTA to contain
more information about the associated clinical trial than
it did. This included 11% of endocrinologists versus 43%
of general internists (P = 0.13), and 31% of CTA Users ver-
sus 50% of CTA Non-users (P = 0.13). Those who indi-
cated "lack of time" as their top reason for dismissing
alerts were also split with 50% indicating that they wanted
the CTA to contain more information. Only 11% felt the
CTA was difficult to use; 27% felt it was more than just
somewhat intrusive.
Endocrinologists generally found the CTA approach less
intrusive than did general internists (Figure 3). Seventy-
three percent were interested in being presented with
CTAs for future trials; this rose overall to 87% if future
CTAs were designed to trigger only for patients with a high
likelihood of eligibility for the trial, and it varied by
degree of specialization and between CTA Users versusBMC Medical Informatics and Decision Making 2008, 8:13 http://www.biomedcentral.com/1472-6947/8/13
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Table 1: Survey Questions
Questions Possible responses
1. Did you know about the existence of the ACCORD clinical trial at 
CCF prior to being presented with the ACCORD Clinical Trial Alert 
(CTA)?
__ Yes __ No
2. Did you appreciate being reminded during the patient encounter that 
your patient might be eligible for the ACCORD clinical trial?
__ Yes __ No
3. How did you respond when presented with the Clinical Trial Alert? __ a. I chose "No" to Cancel the alert EVERY TIME
__ b. I chose "No" to Cancel the alert SOMETIMES
__ c. I always chose "Yes" in order to proceed to the CTA's Smart-Set
__ d. I don't recall
4. If you ever chose "No" to cancel, please rank all reasons in order of 
how frequently they influenced your decision to disregard the CTA: (1-
most common reason, 5-least common reason)
__ I didn't have time to respond
__ I already knew my patient would not qualify for the study
__ I didn't feel knowledgeable enough about the trial to discuss it
__ I felt that discussing this trial would adversely impact the doctor-
patient relationship
__ Other: (please type your other reason(s)): _____
5. How comfortable are you discussing participation in clinical trials with 
your patients, in general?
1-------------2-------------3-------------4-------------5
Uncomfortable Somewhat Comfortable Very Comfortable
6. How comfortable were you asking your patient(s) to consider the 
participating in the ACCORD trial?
1-------------2-------------3-------------4-------------5
Uncomfortable Somewhat Comfortable Very Comfortable or
__(I Never Asked)
7. Overall, how easy was the Clinical Trial Alert system to use? 1-------------2-------------3-------------4-------------5
Difficult Moderately Easy Very Easy
8. Overall, how intrusive did you find the Clinical Trial Alert(s) to be 
during the patient care?
1-------------2-------------3-------------4-------------5
Not Intrusive Somewhat Intrusive Very Intrusive
9. Overall, did you find you wanted more information about the trial 
provided with the alert?
__ Yes, the information provided was NOT adequate
__ No, the information provided was adequate
10. How interested would you be in seeing such alerts for future clinical 
trials?
1-------------2-------------3-------------4-------------5
Not Interested Somewhat Interested Very Interested
11. (part 1) If these alerts were improved so that they appeared only if a 
patient were definitely eligible for a clinical trial, how interested would 
you be in receiving such alerts for future trials?
1-------------2-------------3-------------4-------------5
Not Interested Somewhat Interested Very Interested
11. (part 2) If still not interested, why not? __ a. I'm too busy to participate in such activities
__ b. I don't want to discuss clinical trial participation with my patient
__ c. Other: (please specify)______
12. If your patient were eligible for more than one ongoing clinical trial, 
would you be interested in receiving an alert about each of them, only 
one, or none?
__ a. Each – an alert for each trial and I will choose
__ b. Only one – an alert for the trial that is probably the best fit for my 
patient
__ c. None – I don't want to see any alerts about clinical trials for which 
my patient may be eligible
13. Is this a technology that you would like to use for your future trials? __ a. Yes, I would like to use CTAs for my future clinical trials
__ b. No, I would prefer to use only traditional methods of recruitment
__ c. I do not conduct clinical trials
14. Please provide at least one suggestion for improving the CTA in the 
future?
(free text response)
15. Please provide any additional comments you wish: (free text response)BMC Medical Informatics and Decision Making 2008, 8:13 http://www.biomedcentral.com/1472-6947/8/13
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CTA Non-users (Figure 4). Among the 20% who did not
want the CTA even if it were made more specific, 71%
indicated time constraints to be their main reason. Among
those who wanted to be presented with CTAs in the
future, 42% wanted an alert for each trial for which a
patient may qualify, while 58% wanted a CTA for just the
one "best" trial. Among the 59% percent of respondents
who indicated that they conduct clinical research, 88%
indicated that they would like to use CTAs for their trials.
Respondents' Comments
Narrative comments were submitted by 23 respondents
(33%) and included suggestions for improving the CTA's
content, appearance, or operation. Upon review and anal-
ysis, comments grouped into the categories presented in
Table 2.
Discussion
As EHRs are implemented in practices across the nation,
their use for secondary purposes such as clinical research
will undoubtedly increase. One approach that has already
demonstrated the ability to help overcome the major clin-
ical research obstacle of subject recruitment is the CTA
approach. While this approach holds promise for improv-
ing the quality and efficiency of clinical research, its ulti-
mate utility at the point-of-care rests on understanding
how to make such an approach acceptable to and useful
for clinicians.
As these survey results demonstrate, most internists
exposed to the CTA during our initial intervention study
were generally agreeable to this approach to trial recruit-
ment, even at this early stage in its design. Perhaps not sur-
prisingly, there were some differences between generalists
and subspecialists. Overall, subspecialists were more com-
fortable with trial recruitment in general. Perhaps related
to this, subspecialists were somewhat more positive than
were generalist users regarding the CTA approach, finding
it less intrusive and being a bit more appreciative of it.
However, it is notable that most general internists and
even a substantial minority of respondents who chose to
ignore the CTA altogether still reported being appreciative
of the approach and desired seeing it in the future. Speak-
ing to this in another way is the fact that a surprisingly
large proportion of respondents wished to receive an alert
for each trial for which a future patient might qualify.
While one might question whether these respondents
would really want that if their patient qualified for a
dozen trials ongoing in their region, and while such an
approach would likely be suboptimal with regard to per-
formance, this finding does appear to indicate an accept-
ance of this approach.
Of course, there was also a substantial proportion of
respondents who found flaws with the current CTA
approach. These are perhaps the most useful findings with
regard to next steps in refining this approach. While it was
Perceived intrusiveness of the CTA approach by specialty Figure 3
Perceived intrusiveness of the CTA approach by specialty.
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our goal in designing the CTA approach to limit the infor-
mation presented to clinicians and their need to discuss
the trial in detail with their patients prior to study coordi-
nator referral for full screening, it is clear that many
wished to have more information about the trial available
to them. Indeed, the finding that 50% of CTA non-users
wanted more information about the trial seems to support
the notion that providing such information might
improve responsiveness to the CTA. Furthermore, as
opposed to the challenges in overcoming some limiting
factors such as lack of time to respond, modifying the CTA
to provide a link to additional trial information is cer-
tainly a feasible solution to one identified limitation of
our initial CTA approach. Another factor influencing CTA
effectiveness relates to the balance between sensitivity and
specificity of alerts that must be carefully weighed in
future applications of this approach. What appears clear
from both our intervention study and this survey is that
targeting the CTA more specifically in order to avoid a
high number of false-positive alerts would be welcomed
by most users and might lead to improved CTA usage.
Each of these issues is the focus of ongoing study.
This study has some limitations. While our 61% response
rate is good for a physician survey and no significant dif-
ference in major characteristics of responders versus non-
responders was found, it nevertheless is possible that non-
responders may hold different views that would alter the
results. Also, while the response rate from subspecialists
was quite good, the limited number of subspecialists and
the fact that they represent only one subspecialty mean
that we must be cautious not to over-conclude with regard
to the differences noted between subspecialists and gener-
alists in this survey. Finally, as with our intervention
study, these findings represent the perceptions of a lim-
ited group of practitioners from one health system, using
the CTA approach in a single EHR platform, as applied to
a single clinical trial. Therefore, while informative to those
pursuing this approach in other settings, the generalizabil-
ity of these findings remains to be determined.
Percentage who appreciated being reminded of the CTA approach by (a) specialty and (b) CTA user status Figure 2
Percentage who appreciated being reminded of the CTA approach by (a) specialty and (b) CTA user status.
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Interest in using an EHR-based CTA in the future by (a) specialty and (b) CTA user status Figure 4
Interest in using an EHR-based CTA in the future by (a) specialty and (b) CTA user status.
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Conclusion
Most physicians felt that the CTA approach to point-of-
care trial recruitment was easy to use and would like to see
it used in the future, though subspecialists and generalists
differed somewhat in their perceptions and many would
like to see changes made to the CTA approach. These find-
ings should help to inform future applications and refine-
ment of this EHR-based point-of-care recruitment
approach, and they add to the limited body of knowledge
regarding physicians' attitudes toward clinical trial recruit-
ment in EHR-equipped environments.
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